Acadian Asset Management LLC Sells 26,056 Shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)

Acadian Asset Management LLC decreased its holdings in shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) by 49.7% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 26,390 shares of the specialty pharmaceutical company’s stock after selling 26,056 shares during the quarter. Acadian Asset Management LLC owned 0.20% of Eagle Pharmaceuticals worth $147,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Los Angeles Capital Management LLC boosted its holdings in Eagle Pharmaceuticals by 110.1% during the 1st quarter. Los Angeles Capital Management LLC now owns 191,732 shares of the specialty pharmaceutical company’s stock valued at $1,005,000 after acquiring an additional 100,470 shares during the period. BNP Paribas Financial Markets lifted its position in shares of Eagle Pharmaceuticals by 378.7% during the fourth quarter. BNP Paribas Financial Markets now owns 88,685 shares of the specialty pharmaceutical company’s stock worth $464,000 after purchasing an additional 70,158 shares during the last quarter. Trexquant Investment LP boosted its stake in shares of Eagle Pharmaceuticals by 88.0% during the fourth quarter. Trexquant Investment LP now owns 126,282 shares of the specialty pharmaceutical company’s stock valued at $660,000 after purchasing an additional 59,095 shares during the period. DGS Capital Management LLC grew its holdings in shares of Eagle Pharmaceuticals by 442.5% in the first quarter. DGS Capital Management LLC now owns 61,944 shares of the specialty pharmaceutical company’s stock worth $325,000 after purchasing an additional 50,525 shares during the last quarter. Finally, Jump Financial LLC increased its stake in Eagle Pharmaceuticals by 172.0% in the 4th quarter. Jump Financial LLC now owns 38,900 shares of the specialty pharmaceutical company’s stock worth $203,000 after buying an additional 24,600 shares during the period. 85.36% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, StockNews.com began coverage on shares of Eagle Pharmaceuticals in a research report on Wednesday. They issued a “hold” rating for the company.

Eagle Pharmaceuticals Stock Performance

Shares of NASDAQ EGRX opened at $3.96 on Friday. Eagle Pharmaceuticals, Inc. has a 52-week low of $3.21 and a 52-week high of $15.91. The firm has a market capitalization of $51.43 million, a price-to-earnings ratio of 3.36 and a beta of 0.53. The stock has a 50 day moving average price of $4.70 and a 200 day moving average price of $4.74.

Eagle Pharmaceuticals Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.